WARRINGTON, Pa., Oct. 29, 2014 /PRNewswire/ -- Discovery
Laboratories, Inc. (Nasdaq: DSCO), a specialty
biotechnology company dedicated to advancing a new standard of
respiratory critical care, will report its third quarter 2014
financial results on November 6, 2014
before the open of the U.S. financial markets.
The Company will host a live teleconference and webcast at
9:00 a.m. Eastern Time that same day. During the conference
call, Discovery Labs' management will discuss the 2014 third
quarter financial results along with other business
updates.
The press release and the live webcast of the conference call
will be available via Discovery Labs' corporate website at
www.discoverylabs.com. The webcast will be made available on
the events page. An archive will be available after the call
at the same address until Thursday, November
20, 2014.
To participate in the live conference call, please dial (888)
346-0767 (domestic) or (412) 902-4251 (international). After
placing the call, please ask to be joined into the Discovery Labs
conference call. The conference call replay number is (877)
344-7529 (domestic) or (412) 317-0088 (international); please use
10054486 as the replay passcode.
About Discovery Labs
Discovery Laboratories, Inc. is
a specialty biotechnology company focused on advancing a new
standard in respiratory critical care. Discovery Labs'
technology platforms include a novel proprietary KL4 surfactant, a
synthetic, peptide-containing surfactant that is structurally
similar to pulmonary surfactant, and proprietary drug delivery
technologies being developed to enable efficient delivery of
aerosolized KL4 surfactant. Discovery Labs' strategy is
initially focused on neonatology and improving the management of
respiratory distress syndrome (RDS) in premature infants.
Discovery Labs believes that its RDS product portfolio has the
potential to become the new standard of care for RDS and, over
time, to enable the treatment of a significantly greater number of
premature infants who could benefit from surfactant therapy but are
currently not treated. SURFAXIN® (lucinactant) Intratracheal
Suspension, Discovery Labs' first KL4 surfactant-based product, is
the only available synthetic alternative to animal derived
surfactants approved by the U.S. Food and Drug Administration
(FDA). Full prescribing information can be found at
http://www.surfaxin.com.
For more information, please visit the company's website at
www.Discoverylabs.com.
SOURCE Discovery Laboratories, Inc.